Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 10Glioblastoma 10Breast Neoplasms 10Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Neoplasm Metastasis 7Lung Neoplasms 6Colorectal Neoplasms 6Carcinoma, Hepatocellular 6Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Pancreatic Neoplasms 5Hematologic Neoplasms 5Ovarian Neoplasms 4Myelodysplastic Syndromes 4Multiple Myeloma 4Glioma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Melanoma 3Head and Neck Neoplasms 3Astrocytoma 3Urinary Bladder Neoplasms 2Solid Tumors 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Locally Recurrent Skin Squamous Cell Carcinoma × 90 days × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡